Abstract
Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.
Original language | English (US) |
---|---|
Pages (from-to) | 70-81 |
Number of pages | 12 |
Journal | Translational Research |
Volume | 225 |
DOIs | |
State | Published - Nov 2020 |
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Physiology (medical)
- Biochemistry, medical